Evidence map›Paper›PMID 30703129›Full record

Trial reportPloS one2019

Mortality risk in adults according to categories of impaired glucose metabolism after 18 years of follow-up in the North of Spain: The Asturias Study.

Jessica Ares, Sergio Valdés, Patricia Botas, Cecilia Sánchez-Ragnarsson, Sandra Rodríguez-Rodero, Paula Morales-Sánchez, Edelmiro Menéndez-Torre, Elías Delgado

Erratum issuedAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Tight and early HbAFrontiers in public health · 2025
    Article
  3. Article
  4. Article
  5. Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jessica AresAsturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Asturias, Spain.ORCID 0000-0002-4307-8145
Sergio ValdésMálaga Regional University Hospital, Endocrinology and Nutrition Department, Málaga, Andalucía, Spain.
Patricia BotasSan Agustín University Hospital, Endocrinology Department, Avilés, Asturias, Spain.
Cecilia Sánchez-RagnarssonAsturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Asturias, Spain.
Sandra Rodríguez-RoderoAsturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Asturias, Spain.
Paula Morales-SánchezAsturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Asturias, Spain.
Edelmiro Menéndez-TorreAsturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Asturias, Spain.
Elías DelgadoAsturias Central University Hospital, Endocrinology and Nutrition Department, Oviedo, Asturias, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People who develop type 2 diabetes (T2D) are known to have a higher mortality risk. We estimated all-cause, cardiovascular, and cancer mortality-risks in our patient cohort according to categories of impaired glucose metabolism. This 18-year retrospective analysis included a region-wide, representative sample of a population aged 30-75 years. Age- and sex-stratified hazard ratios (HRs) were calculated for 48 participants with diagnosed T2D, 83 with undiagnosed T2D (HbA1c ≥6.5%, fasting glycemia ≥126 mg/dL, or glycemia after 75 g glucose load ≥200 mg/dL); 296 with prediabetes (HbA1c 5.7%-6.4%, fasting glycemia 100-125 mg/dL, or glycemia after 75 g glucose load 140-199 mg/dL), and 607 with normoglycemia. Over 18,612 person-years, 32 individuals with undiagnosed T2D, 30 with diagnosed T2D, 62 with prediabetes, and 80 with normoglycemia died. Total sample crude mortality rate (MR) was 10.96 deaths per 1,000 person-years of follow-up. MR of the diagnosed T2D group was more than 3-times higher and that of newly diagnosed T2D was 2-times higher (34.72 and 21.42, respectively) than total sample MR. Adjusted HR for all-cause mortality was 2.02 (95% confidence interval 1.29-3.16) and 1.57 (95% CI 1.00-2.28) in the diagnosed T2D group and the newly diagnosed T2D group, respectively. Adjusted HR for cardiovascular mortality in the T2D group was 2.79 (95% CI 1.35-5.75); this risk was greatly increased in women with T2D: 6.72 (95% CI 2.50-18.07). In Asturias, age- and sex-standardized all-cause mortality is more than 2-times higher for adults with T2D than for adults without T2D. The HR for cardiovascular mortality is considerably higher in T2D women than in normoglycemic women.

Indexed as

AdultAgedAge FactorsBlood GlucoseCardiovascular DiseasesDiabetes ComplicationsDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHumansMaleMiddle AgedPrediabetic StateRetrospective StudiesRisk FactorsSex FactorsBlood Glucose

Identifiers

PMID30703129
PMCPMC6354980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.